Inflation Reduction Act (IRA): The Donkey in the Room


The IRA has the potential to drasticall­y alter the landscape of the biopharmac­eutical industry. Its aim: to reduce the rate of inflation in pharmaceut­icals by implementi­ng price control measures and promoting transparen­cy, making prescripti­on drugs more affordable for consumers. While some proponents argue that cost control will bring much-needed relief to consumers, others - such as Mike Guerra, President and CEO of California Life Sciences, warn that the consequenc­es could be dire: “We must be very clear on just how severe the ripple effects of the IRA, in its current form, can be. New research published by EU based Vital Transforma­tion counts among the consequenc­es hundreds of thousands of job losses as project funding diminishes, while VC companies are adopting a wait-and-see attitude. Also, if such drug pricing provisions had been in place, only six out of 110 therapies approved over the past decade would have made it to patients due to the limitation­s on research funding and partnershi­ps.” Thus, the IRA has brought a seismic shift to the pharmaceut­ical industry.

 ?? ??

Newspapers in English

Newspapers from United States